NEWS COMMENTARY

Solar Foods grabs $18 million in new Series A funding

Published:
September 02, 2020
Coverage:
Emerging Ecosystems in Agrifood and Health More...
Activities:
Investment
by Thomas Hayes
Average importance

This brings its total Series A financing to $22 million, including the convertible note it received in September 2019. Finnish food company Fazer Group led the round, with other notable investors including Agronomics and CPT Capital. The funding will be used to construct a commercial production facility, aimed to be operational by the end of 2022. While this is a step forward, the company still has not obtained novel food authorization from the EFSA. Moreover, while it claims to have developed 20 different kinds of food products using its protein ingredient Solein, the sensory profile of those foods is still unknown and questionable. Clients, don't get swept up in the CO2-to-protein hype quite yet. There are still many barriers to clear.

For the original news article, click here .


Further Reading

Provivi receives $20 million loan facility from Horizon signifying strategy move

News Commentary | June 24, 2020

This loan will be applied to growth and general corporate needs, and indicates several developmental characteristics of Provivi. First, the company is likely making good progress in its efforts to commercialize, as these loans are typically paid back in monthly intervals. Second, it suggests that ... Not part of subscription

BlueNalu looks to commercialize cell-based seafood with $60 million funding

News Commentary | January 22, 2021

Led by Rage Capital, this convertible note financing will help BlueNalu realize its commercialization plans, including the completion of a 40,000 ft2 pilot facility in the U.S. This funding round also places BlueNalu as the front‑runner in the cell‑based seafood space. The company's first product is... To read more, click here.

Growing momentum for mycoproteins in Europe as Enough and Mycorena raise funding

News Commentary | June 24, 2021

Just this week, two European mycoproteins startups raised funding: Enough raised $51 million in a Series B round led by Nutreco, and Mycorena raised a $9 million pre‑Series A round led by Belgian ingredient company Veos. This cash injection will help both companies to develop their respective ... Not part of subscription